Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Paclitaxel for Metastatic HER2-Negative Breast Cancer
NCT00622466Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Apr 2008
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in breast cancer, sponsored by UT Southwestern Medical Center. Primary endpoint: Time to Tumor Progression up to 36 months. Started Apr 2008; status: terminated.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00622466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00622466.